keyword
MENU ▼
Read by QxMD icon Read
search

comorbidity index in systemic lupus erythematosus

keyword
https://www.readbyqxmd.com/read/28298561/charlson-comorbidity-index-is-related-to-organ-damage-in-systemic-lupus-erythematosus-data-from-korean-lupus-network-kornet-registry
#1
Seong-Kyu Kim, Jung-Yoon Choe, Shin-Seok Lee
OBJECTIVE: The aim of this study was to identify whether comorbidity status is associated with organ damage in patients with systemic lupus erythematosus (SLE). METHODS: A total of 502 patients with SLE enrolled in the KORean lupus Network were consecutively recruited. Data included demographics, age-adjusted Charlson Comorbidity Index (CCIa), disease activity indexes, the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI), the Medical Outcomes Study Short Form-36 health survey (SF-36) score, and the Beck Depression Inventory (BDI) score...
March 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28286903/the-risk-of-tuberculosis-in-sle-patients-from-an-asian-tertiary-hospital
#2
Yong Yang, Julian Thumboo, Ban Hock Tan, Thuan Tong Tan, Chern Hui Jeffrey Fong, Han Seong Ng, Kok Yong Fong
Systemic lupus erythematosus (SLE) has been associated with increased risk of tuberculosis (TB). However, little is known about the extent and risk factors for TB among Asian patient with SLE. We aimed to assess the rate of TB in patients with SLE, and investigate the risk of SLE on TB development using hospital administrative database. This is an historical cohort study of hospital discharge database from 2004 to 2011 to identify cases with SLE and TB using International Statistical Classification of Diseases and Related Health Problems, 9th Revision, Australian Modification (ICD-9-AM) codes...
March 12, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28259425/incidence-associated-factors-and-clinical-impact-of-severe-infections-in-a-large-multicentric-cohort-of-patients-with-systemic-lupus-erythematosus
#3
Íñigo Rúa-Figueroa, Javier López-Longo, María Galindo-Izquierdo, Jaime Calvo-Alén, Víctor Del Campo, Alejandro Olivé-Marqués, Sabina Pérez-Vicente, Antonio Fernández-Nebro, Mariano Andrés, Celia Erausquin, Eva Tomero, Loreto Horcada, Esther Uriarte, Mercedes Freire, Carlos Montilla, Ana Sánchez-Atrio, Gregorio Santos, Alina Boteanu, Elvira Díez-Álvarez, Javier Narváez, Víctor Martínez-Taboada, Lucía Silva-Fernández, Esther Ruiz-Lucea, José Luis Andreu, José Ángel Hernández-Beriain, Marian Gantes, Blanca Hernández-Cruz, José Pérez-Venegas, Ángela Pecondón-Español, Carlos Marras, Mónica Ibáñez-Barceló, Gema Bonilla, Vicente Torrente, Iván Castellví, Juan José Alegre, Joan Calvet, Jose Luis Marenco, Enrique Raya, Tomás Vázquez, Victor Quevedo, Santiago Muñoz-Fernández, Manuel Rodríguez-Gómez, Jesús Ibáñez, José M Pego-Reigosa
OBJECTIVES: To estimate the incidence of severe infection and investigate the associated factors and clinical impact in a large systemic lupus erythematosus (SLE) retrospective cohort. METHODS: All patients in the Spanish Rheumatology Society Lupus Registry (RELESSER) who meet ≥4 ACR-97 SLE criteria were retrospectively investigated for severe infections. Patients with and without infections were compared in terms of SLE severity, damage, comorbidities, and demographic characteristics...
January 27, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28178878/disease-characterization-of-systemic-lupus-erythematosus-sle-patients-in-quebec
#4
R Ng, S Bernatsky, E Rahme
Objective Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by an array of organ manifestations that can appear during flares and disappear during remissions. The objectives of this study were: (i) to examine SLE manifestation groups longitudinally in an SLE cohort; and (ii) to assess the association between early antimalarial treatment and renal manifestations. Methods Seven SLE manifestation groups-cutaneous, hematologic, lung, musculoskeletal, neuropsychiatric, serositis, renal-were tracked using Kaplan-Meier survival curves in an incident SLE cohort from Quebec health administrative data ( n = 2010)...
January 1, 2017: Lupus
https://www.readbyqxmd.com/read/27799439/systemic-lupus-erythematosus-in-spanish-males-a-study-of-the-spanish-rheumatology-society-lupus-registry-relesser-cohort
#5
A Riveros Frutos, I Casas, I Rúa-Figueroa, F J López-Longo, J Calvo-Alén, M Galindo, A Fernández-Nebro, J M Pego-Reigosa, A Olivé Marqués
OBJECTIVE: The objective of this study was to describe the demographic, clinical, and immunological manifestations of systemic lupus erythematosus (SLE) in male patients. METHODS: A cross-sectional, multicenter study was carried out of 3651 patients (353 men, 9.7%, and 3298 women, 90.2%) diagnosed with SLE, included in the Spanish Rheumatology Society SLE Registry (RELESSER). RESULTS: Mean ages (18-92 years) of symptom onset were 37 (SD 17) years (men) and 32 (SD 14) years (women)...
October 31, 2016: Lupus
https://www.readbyqxmd.com/read/27534653/medical-costs-incurred-by-organ-damage-caused-by-active-disease-comorbidities-and-side-effect-of-treatments-in-systemic-lupus-erythematosus-patients-a-taiwan-nationwide-population-based-study
#6
Y M Chiu, M T Chuang, H C Lang
This study aims to systematically investigate the medial expenditures incurred by systemic lupus erythematosus (SLE)-associated organ damages in order to assess the economic impact of damage accrual by active disease, comorbidities and side effect of treatments. In total, 22,258 SLE cases were identified from the National Health Insurance Research Database, and organ damages assessed were according to the list from Systemic Lupus International Collaborative Clinic/American Rheumatology damage index system. Medical expenditures incurred by organ damages in the first as well as the subsequent year were obtained from the database...
November 2016: Rheumatology International
https://www.readbyqxmd.com/read/27444335/validation-of-an-argentine-version-of-lupus-quality-of-life-questionnaire
#7
M A Machado Escobar, M S Yacuzzi, R N Martinez, L González Lucero, V I Bellomio, M Santana, L Galindo, M M Mayer, J C Barreira, J Sarano, G Gomez, M V Collado, A Martinez, M C Orozco, G Betancur, F Dal Pra, A Sanchez, V Juarez, E V Lucero
OBJECTIVE: To determine reproducibility and validity of an Argentine version of the Lupus Quality of Life questionnaire (LupusQoL) and to determine cut-off values in the questionnaire. MATERIALS AND METHODS: One hundred and forty-seven systemic lupus erythematosus patients (American College of Rheumatology 1982/1997) were assessed from April 2014 to July 2014. Demographic and socioeconomic variables were collected, as well as SELENA/SLEDAI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index Score, comorbidities and treatment data...
December 2016: Lupus
https://www.readbyqxmd.com/read/27412038/survival-rates-of-cancer-patients-with-and-without-rheumatic-disease-a-retrospective-cohort-analysis
#8
Jin Kyun Park, Ji Ae Yang, Eun Young Ahn, Sung Hae Chang, Yeong Wook Song, Jeffrey R Curtis, Eun Bong Lee
BACKGROUND: To compare the outcomes of gastric, colon, lung, and breast cancer patients with and without rheumatic diseases (RD). METHODS: This retrospective study compared the cancer survival rates of a cohort of 122 cancer patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), dermatomyositis/polymyositis (DM/PM), or systemic sclerosis with that of a cohort of 366 age-, sex-, and, cancer type-matched patients without RD who received medical care from 2000 to 2014...
2016: BMC Cancer
https://www.readbyqxmd.com/read/27197885/-dyslipidaemia-and-atherogenic-risk-in-patients-with-systemic-lupus-erythematosus
#9
José Antonio de Jesús Batún Garrido, Hugo Alberto Radillo Alba, Éufrates Hernández Núñez, Francisco Olán
INTRODUCTION: Dyslipidaemia is a common comorbidity in patients with systemic lupus erythematosus. PATIENTS AND METHODS: Fifty-one patients were included. Variables associated with the disease and the drugs used were recorded. Atherogenic risk was calculated. Chi square was used for categorical variables. ANOVA was performed and a logistic regression model to determine the association of the variables with the presence of dyslipidaemia. RESULTS: A percentage of 68...
July 15, 2016: Medicina Clínica
https://www.readbyqxmd.com/read/26876691/insomnia-symptoms-perceived-stress-and-coping-strategies-in-patients-with-systemic-lupus-erythematosus
#10
L Palagini, M Mauri, U Faraguna, L Carli, C Tani, L Dell'Osso, M Mosca, D Riemann
OBJECTIVE: The aim of this study is to evaluate perceived stress and coping strategies in individuals with systemic lupus erythematosus (SLE) according to the presence of insomnia symptoms, using a set of variables that include anxiety and depressive symptoms evaluation. METHODS: Ninety SLE women were evaluated in a cross-sectional study using the Perceived Stress Scale (PSS), Brief COPE, Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Beck Depression Inventory (BDI) and Self-rating Anxiety Scale (SAS)...
August 2016: Lupus
https://www.readbyqxmd.com/read/26848397/risk-factors-for-osteoporosis-and-fragility-fractures-in-patients-with-systemic-lupus-erythematosus
#11
L Carli, C Tani, V Spera, R Vagelli, S Vagnani, M Mazzantini, O Di Munno, M Mosca
Osteoporosis (OP) and fragility fractures (FFx) are a known comorbidity in patients with systemic lupus erythematosus (SLE). This work aimed at evaluating (1) the prevalence of OP and FFx in a cohort of SLE and (2) the risk factors associated with both OP and FFx. The following data were collected from clinical charts: age, sex, menopausal status (MP), body mass index, smoking habits, disease duration, daily dose and cumulative glucocorticoids (GCs), type of organ involvement, comorbidities and medications...
2016: Lupus Science & Medicine
https://www.readbyqxmd.com/read/26809011/treat-to-target-in-systemic-lupus-erythematosus-are-we-there-yet
#12
Chi Chiu Mok
The treat-to-target (T2T) strategy has proven benefits in several chronic medical illnesses including rheumatoid arthritis. Whether the T2T principle can be applied to SLE has become a recent topic of discussion. A European panel of rheumatologists agrees that treatment of SLE should target at multiple goals that include control of disease activity, prevention of disease flares, minimization of disease or treatment related comorbidity, and improvement of quality of life. Therapy of SLE should aim at remission or when remission cannot be achieved, the lowest possible disease activity that is assessed by a validated lupus activity index and/or organ-specific markers...
2016: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/26585071/association-of-systemic-lupus-erythematosus-and-sleep-disorders-a-nationwide-population-based-cohort-study
#13
W S Chung, C L Lin, C H Kao
OBJECTIVE: Using a population-based cohort study, we investigated whether sleep disorders (SDs) increase the risk of systemic lupus erythematosus (SLE). PATIENTS AND METHODS: We identified patients with SDs and a control cohort from 1998-2001 by using the Taiwan Longitudinal Health Insurance Database 2000. Two controls for each patient with an SD were selected and randomly frequency-matched according to age, gender, and index year. The follow-up person-years were estimated for the patients from the index date to SLE diagnosis, loss to follow-up, or the end of 31 December 2011...
April 2016: Lupus
https://www.readbyqxmd.com/read/26097166/medication-nonadherence-is-associated-with-increased-subsequent-acute-care-utilization-among-medicaid-beneficiaries-with-systemic-lupus-erythematosus
#14
Candace H Feldman, Jinoos Yazdany, Hongshu Guan, Daniel H Solomon, Karen H Costenbader
OBJECTIVE: We examined whether nonadherence to hydroxychloroquine (HCQ) or immunosuppressive medications (ISMs) was associated with higher subsequent acute care utilization among Medicaid beneficiaries with systemic lupus erythematosus (SLE). METHODS: We utilized US Medicaid data from 2000-2006 to identify adults ages 18-64 years with SLE who were new users of HCQ or ISMs. We defined the index date as receipt of HCQ or ISMs without use in the prior 6 months. We measured adherence using the medication possession ratio (MPR), the proportion of days covered by total days' supply dispensed, for the 1-year post-index date...
December 2015: Arthritis Care & Research
https://www.readbyqxmd.com/read/25732944/-cormorbidity-in-multiple-sclerosis-and-its-therapeutic-approach
#15
REVIEW
Bonaventura Casanova Estruch
Multiple sclerosis (MS) is a long-term chronic disease, in which intercurrent processes develop three times more frequently in affected individuals than in persons without MS. Knowledge of the comorbidity of MS, its definition and measurement (Charlson index) improves patient management. Acting on comorbid conditions delays the progression of disability, which is intimately linked to the number of concurrent processes and with health states and habits. Moreover, the presence of comorbidities delays the diagnosis of MS, which in turn delays the start of treatment...
December 2014: Medicina Clínica
https://www.readbyqxmd.com/read/25586653/dissecting-the-damage-in-northern-greek-patients-with-childhood-onset-systemic-lupus-erythematosus-a-retrospective-cohort-study
#16
Artemis Koutsonikoli, Maria Trachana, Anna-Bettina Heidich, Vasiliki Galanopoulou, Polyxeni Pratsidou-Gertsi, Alexandros Garyphallos
The improved survival of childhood-onset systemic lupus erythematosus (cSLE) has resulted in longer patients' exposure to disease inflammation, medications and/or comorbid diseases, which can all contribute to the development of organ damage. The aim of this study was to assess the evolution of damage accrual in cSLE patients overtime and investigate for predisposing factors. Disease characteristics and treatment in 47 Northern Greek Caucasian cSLE patients were retrospectively reviewed. The Systemic Lupus International Collaboration Clinics/American College of Rheumatology Damage Index (SDI) was used for damage assessment and the European Consensus Lupus Activity Measurement (ECLAM) to monitor cSLE activity...
July 2015: Rheumatology International
https://www.readbyqxmd.com/read/25569641/comprehensive-description-of-clinical-characteristics-of-a-large-systemic-lupus-erythematosus-cohort-from-the-spanish-rheumatology-society-lupus-registry-relesser-with-emphasis-on-complete-versus-incomplete-lupus-differences
#17
MULTICENTER STUDY
Íñigo Rúa-Figueroa, Patricia Richi, Francisco Javier López-Longo, María Galindo, Jaime Calvo-Alén, Alejandro Olivé-Marqués, Estíbaliz Loza-Santamaría, Sabina Pérez Vicente, Celia Erausquin, Eva Tomero, Loreto Horcada, Esther Uriarte, Ana Sánchez-Atrio, José Rosas, Carlos Montilla, Antonio Fernández-Nebro, Manuel Rodríguez-Gómez, Paloma Vela, Ricardo Blanco, Mercedes Freire, Lucía Silva, Elvira Díez-Álvarez, Mónica Ibáñez-Barceló, Antonio Zea, Javier Narváez, Víctor Martínez-Taboada, José Luis Marenco, Mónica Fernández de Castro, Olaia Fernández-Berrizbeitia, José Ángel Hernández-Beriain, Marian Gantes, Blanca Hernández-Cruz, José J Pérez-Venegas, Ángela Pecondón, Carlos Marras, Patricia Carreira, Gema Bonilla, Vicente Torrente, Iván Castellví, Juan Alegre, Mireia Moreno, Enrique Raya, Paloma García de la Peña, Tomás Vázquez, Ángeles Aguirre, Víctor Quevedo, José M Pego-Reigosa
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple organ involvement and pronounced racial and ethnic heterogeneity. The aims of the present work were (1) to describe the cumulative clinical characteristics of those patients included in the Spanish Rheumatology Society SLE Registry (RELESSER), focusing on the differences between patients who fulfilled the 1997 ACR-SLE criteria versus those with less than 4 criteria (hereafter designated as incomplete SLE (iSLE)) and (2) to compare SLE patient characteristics with those documented in other multicentric SLE registries...
January 2015: Medicine (Baltimore)
https://www.readbyqxmd.com/read/25328393/optimal-management-of-fatigue-in-patients-with-systemic-lupus-erythematosus-a-systematic-review
#18
REVIEW
Hon K Yuen, Melissa A Cunningham
Among the host of distressing pathophysiological and psychosocial symptoms, fatigue is the most prevalent complaint in patients with systemic lupus erythematosus (SLE). This review is to update the current findings on non-pharmacological, pharmacological, and modality strategies to manage fatigue in patients with SLE and to provide some recommendations on optimal management of fatigue based on the best available evidence. We performed a systematic literature search of the PubMed and Scopus databases to identify publications on fatigue management in patients with SLE...
2014: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/25111878/atopic-diseases-and-systemic-lupus-erythematosus-an-epidemiological-study-of-the-risks-and-correlations
#19
Yu-Ping Hsiao, Jeng-Dau Tsai, Chih-Hsin Muo, Chung-Hung Tsai, Fung-Chang Sung, Ya-Tang Liao, Yen-Jung Chang, Jen-Hung Yang
Both atopic diseases and systemic lupus erythematosus (SLE) are immune disorders that may lead to physical complications or multi-system comorbidities. This population-based case-control study was designed to evaluate the risk of SLE associated with atopic diseases. Using a national insurance claims dataset in Taiwan, we identified 1673 patients newly diagnosed with SLE and 6692 randomly selected controls frequency matched for gender, age and index date. The odds ratios (OR) for SLE were calculated for associations with allergic rhinitis, allergic conjunctivitis, atopic dermatitis and asthma...
August 2014: International Journal of Environmental Research and Public Health
https://www.readbyqxmd.com/read/25086072/clinical-and-immunogenetic-factors-associated-with-pneumonia-in-patients-with-systemic-lupus-erythematosus-a-case-control-study
#20
Iñigo Rúa-Figueroa, Javier Nóvoa, María Isabel García-Laorden, Celia Erausquin, Miguel García-Bello, Felipe Rodríguez de Castro, Estefanía Herrera-Ramos, Soledad Ojeda, Juan Carlos Quevedo, Félix Francisco, Antonio Naranjo, Carlos Rodríguez-Lozano, Carlos Rodríguez-Gallego
OBJECTIVE: To determine the incidence of pneumonia and associated factors in a single-center systemic lupus erythematosus (SLE) cohort. METHODS: We included all our SLE patients [1997 American College of Rheumatology (ACR) criteria] with ≥ 1 pneumonia event, and 196 age and sex-matched SLE controls with no pneumonia events. Cumulative clinical data, weighted Systemic Lupus International Collaborating Clinics/ACR damage index (wSLICC/ACR-DI), comorbidities, and risk factors for pneumonia were retrospectively collected...
September 2014: Journal of Rheumatology
keyword
keyword
66979
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"